Amyloid β Levels in Human Red Blood Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kiko, Takehiro ^a   Nakagawa, Kiyotaka ^a   Satoh, Akira ^b   Tsuduki, Tsuyoshi ^a   Furukawa, Katsutoshi ^a   Arai, Hiroyuki ^a   Miyazawa, Teruo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b YAMAHA MOTOR CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ASTAXANTHIN; BIOLOGICAL MARKER; PLACEBO; PURESTA; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ADULT; AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; DIETARY SUPPLEMENTS; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; XANTHOPHYLLS; YOUNG ADULT;

EID: 84869208877     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049620     Document Type: Article

References (40)

1. de la Torre JC, (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190.
2. Younkin SG, (1995) Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 37: 287-288.
3. Scheuner D, Eckman C, Jensen M, Song X, Citron M, et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870.
4. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, et al. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57: 100-105.
5. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM, (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5: 655-660.
6. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, et al. (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 64: 354-362.
7. Mattson MP, Begley JG, Mark RJ, Furukawa K, (1997) Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res 771: 147-153.
8. Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM, (2008) Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer's disease? Adv Exp Med Biol 614: 29-35.
9. Nakagawa K, Kiko T, Miyazawa T, Sookwong P, Tsuduki T, et al. (2011) Amyloid β-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett 585: 1249-1254.
10. Jayakumar R, Kusiak JW, Chrest FJ, Demehin AA, Murali J, et al. (2003) Red cell perturbations by amyloid beta-protein. Biochim Biophys Acta 1622: 20-28.
11. Nakagawa K, Kiko T, Kuriwada S, Miyazawa T, Kimura F, et al. (2011) Amyloid β induces adhesion of erythrocytes to endothelial cells and affects endothelial viability and functionality. Biosci Biotechnol Biochem 75: 2030-2033.
12. Nakagawa K, Kiko T, Miyazawa T, Carpentero Burdeos G, Kimura F, et al. (2011) Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes. Br J Nutr 105: 1563-1571.
13. Kiko T, Nakagawa K, Tsuduki T, Suzuki T, Arai H, et al. (2012) Significance of lutein in red blood cells of Alzheimer's disease patients. J Alzheimers Dis. 28: 593-600.
14. Nakagawa K, Kiko T, Hatade K, Sookwong P, Arai H, et al. (2009) Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes. Br J Nutr 102: 1280-1284.
15. Nakagawa K, Kiko T, Hatade K, Asai A, Kimura F, et al. (2008) Development of an HPLC-based assay for carotenoids in human red blood cells: application to clinical studies. Anal Biochem 381: 129-134.
16. Miyazawa T, Suzuki T, Fujimoto K, Yasuda K, (1992) Chemiluminescent simultaneous determination of phosphatidylcholine hydroperoxide and phosphatidylethanolamine hydroperoxide in the liver and brain of the rat. J Lipid Res 33: 1051-1059.
17. Hosoda R, Saido TC, Otvos L Jr, Arai T, Mann DM, et al. (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 57: 1089-1095.
18. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, et al. (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013.
19. Moghekar A, Goh J, Li M, Albert M, O'Brien RJ, (2012) Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol 69: 246-250.
20. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, et al. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336-1340.
21. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, et al. (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61: 1185-1190.
22. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, et al. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
23. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, et al. (1996) Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67: 880-883.
24. Zlokovic BV, (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811.
25. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, et al. (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330: 980-982.
26. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855.
27. Chen M, Inestrosa NC, Ross GS, Fernandez HL, (1995) Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun 213: 96-103.
28. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, et al. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57: 100-105.
29. Kuo YM, Kokjohn TA, Kalback W, Luchrs D, Galasko DR, et al. (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268: 750-756.
30. Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, et al. (1996) Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. J Biol Chem 271: 28757-28765.
31. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, et al. (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60: 958-964.
32. Mohanty JG, Eckley DM, Williamson JD, Launer LJ, Rifkind JM, (2008) Do red blood cell-beta-amyloid interactions alter oxygen delivery in Alzheimer's disease? Adv Exp Med Biol 614: 29-35.
33. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, et al. (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45: 537-541.
34. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, et al. (2004) Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 189: 380-392.
35. Takasaki J, Ono K, Yoshiike Y, Hirohata M, Ikeda T, et al. (2011) Vitamin A has anti-oligomerization effects on amyloid-β in vitro. J Alzheimers Dis 27: 271-280.
36. Hone E, Martins IJ, Fonte J, Martins RN, (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5: 1-8.
37. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, et al. (2004) Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279: 45897-45908.
38. Tamaki C, Ohtsuki S, Terasaki T, (2004) Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279: 45897-45908.
39. Butterfield DA, (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36: 1307-1313.
40. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA, (1999) Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res Bull 50: 133-141.